Advanced search    

Search: authors:"Evo Alemao"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis

association of HAQ change by baseline DAS categories. (DOCX) Author Contributions Formal analysis: Evo Alemao. Methodology: Evo Alemao. Conceptualization: Evo Alemao, Maiwenn J. Al, Maureen P. M. H. Rutten ... . Writing ± original draft: Evo Alemao. Writing ± review & editing: Maiwenn J. Al, Annelies A. Boonen, Matthew D. Stevenson, Suzanne M. M. Verstappen, Kaleb Michaud, Michael E. Weinblatt, Maureen P. M. H

Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort

assistance was provided by Stacey Reeber, PhD, at Caudex and was funded by Bristol-Myers Squibb. Disclosures. Harris A. Ahmad is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Evo ... Alemao is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Zhenchao Guo is an employee of and has stock options/bond holdings in Bristol-Myers Squibb. Michael Weinblatt has

Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept

France; consulting fees: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche, UCB; board member: Executive Committee of OMERACT. Souhila Ahdjoudj: employee: Bristol-Myers Squibb. Evo ... Alemao: shareholder and employee: Bristol-Myers Squibb. Vibeke Strand: consulting fees: AbbVie, Alder, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Celltrion, Corrona, Crescendo Bioscience, Genentech

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naïve patients with rheumatoid arthritis (RA) initiating abatacept in clinical practice. Using the Corrona RA registry (February 2006–January 2015), biologic-naïve patients with RA initiating abatacept with 12-month (±3 months) follow-up and assessment of...